Compare Aurora Cannabis Inc (ACB) vs Apartment Investment and Management Co (AIV) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

AIV trades at $2.66, up 0.38% on the day, with a bearish technical signal from moving averages. The company reported a net income margin of 400.05% in 2025, driven by a significant tax benefit, though revenue declined to $138.49 million. Earnings history shows mixed quarterly results, with two beats and two misses against expectations. Analyst consensus is mixed with a hold rating from two of three analysts.

The outlook is cautious due to volatile earnings and declining revenue, offset by strong profitability metrics and a dividend announcement. Key risks include inconsistent financial performance and high debt levels. Upside potential exists if the company stabilizes revenue growth and maintains improved margins.